Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GB06 in Pediatric Growth Hormone Deficiency
NCT07553351Phase 3Recruiting
- Sponsor
- Kexing Biopharm
- Start
- Jun 2026
- Primary completion
- Jul 2028
- Modality
- Hormone, rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of somatropin in growth hormone deficiency (GHD) (2 arms), sponsored by Kexing Biopharm. Primary endpoint: Annual height velocity at 52 weeks. Started Jun 2026; status: recruiting.
02
Drugs
somatropin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT07553351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07553351.